Pattharasai Kachornvitaya

Pattharasai Kachornvitaya

Auto-generated profile, based on publicly available information

Pattharasai Kachornvitaya

Digestive Disease Institute, Cleveland Clinic, Ohio; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
KKKritsada Kongsawat
Kritsada Kongsawat
KCKomol Chaivanijchaya
Komol Chaivanijchaya
FPFon Pakul
Fon Pakul
SJSuthikiat Joradol
Suthikiat Joradol
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
SUSuthep Udomsawaengsup
Suthep Udomsawaengsup
Venous thromboembolism (VTE) is a common cause of morbidity and mortality after bariatric surgery. Morbid obesity is an independent risk factor for VTE, with goals of prophylactic anti-factor Xa levels within 0.2-0.5 IU/mL. The recommended dosing regimen of enoxaparin for VTE prophylaxis in patients with morbid obesity is lacking in available guidelines. To evaluate the achieving prophylactic anti-factor Xa levels with different dosages of enoxaparin for morbid obesity patients. We conducted a study at Chulalongkorn Bariatric and Metabolic Institute, King Chulalongkorn Memorial Hospital. We conducted a randomized controlled trial comparing anti-factor Xa levels 4 h after the administration of enoxaparin. All recruited patients randomly received 40 mg or 60 mg of enoxaparin 12 h before the operation. Blood specimens were collected 4 h after the administration of enoxaparin. In total, 56 patients who presented between April 2019 and March 2020 at King Chulalongkorn Memorial Hospital were recruited. Of these patients, 28 received 40 mg and 28 received 60 mg of enoxaparin. In both groups, the rates of achieving target levels were 53.57% and 78.57%, respectively (p-value = 0.048). The mean anti-factor Xa levels were 0.19 IU/mL ± 0.06 IU/mL and 0.28 and 0.28 ± 0.10 IU/mL, respectively (p < 0.001). No significant difference was found in the estimated blood loss between the groups. No patient obtained anti-factor Xa levels exceeding 0.5 IU/mL. In both groups, no symptomatic VTE occurred. A 60 mg of enoxaparin regimen achieved more prophylactic anti-factor Xa levels than 40 mg in obese patients undergoing bariatric surgery without any adverse events.

17 March 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
MWMélissa V. Wills
Mélissa V. Wills
SLSol Lee
Sol Lee
VMValentin Mocanu
Valentin Mocanu
YLYung Lee
Yung Lee
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
RCRicard Corcelles
Ricard Corcelles
Weight recurrence and suboptimal response after metabolic and bariatric surgery (MBS) lack standardized definitions and management approaches, creating barriers to evidence-based treatment decisions and coordinated care across multiple specialties. To establish international expert consensus on terminology, diagnostic approaches, and management strategies for suboptimal response and weight recurrence after MBS. International Delphi study across multiple countries and health care systems. A two-round modified Delphi study was conducted with 66 international experts across five specialties (MBS, obesity medicine, gastroenterology, endocrinology, dietetics and nutrition, and psychology). A 164-item questionnaire was developed, spanning seven dimensions: conservative management, diagnostic methods, endoscopic interventions, quantitative thresholds, risk factors, surgical interventions, and terminology. Consensus was defined a priori as ≥70% agreement. Inter-rater reliability was assessed using Gwet's AC1 coefficient. Response rates were 54.5% (Round 1) and 57.6% (Round 2). Consensus achievement improved significantly between rounds (26.2% to 40.9% of items). Experts reached unanimous agreement on core management principles including individualized patient care (100%) and the appropriateness of specialists prescribing antiobesity medications (100%). Strong consensus emerged on standardized terminology with "suboptimal" as the preferred term (89.5%) and %TWL as the optimal measurement approach (94.6). For quantitative thresholds, consensus was achieved on surgical nonresponse defined as 25% of lost weight from nadir (70.3%), and a 10% change in %EWL from nadir as normal physiologic response (83.8%). Conservative management items achieved the highest consensus rates (80.9%) while quantitative threshold items require additional research (28.1%). Inter-rater reliability improved across all domains, with conservative management achieving substantial agreement (AC1 = .70). Expert consensus was achieved on fundamental principles of postbariatric care, including preferred terminology, measurement metrics, and provider roles. These recommendations address important gaps in clinical practice standardization.

10 October 2025 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
XZXinlei Zhu
Xinlei Zhu
QWQi Wang
Qi Wang
VMValentin Mocanu
Valentin Mocanu
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
MWMélissa V. Wills
Mélissa V. Wills
Jerry DangJerry Dang
Jerry Dang
Obesity and rheumatoid arthritis (RA) are chronic, often coexisting conditions that compound clinical complexity. Metabolic and bariatric surgery (MBS) is an effective treatment for severe obesity, but its long-term safety and impact on RA disease control are not well defined. To evaluate the long-term safety (≤5 years) and potential disease-modifying effects of MBS in patients with RA. Multicenter, retrospective cohort study using the TriNetX global federated health research network across multiple healthcare institutions worldwide. Adults (≥18 years) who underwent MBS between 2010 and 2024 were identified. Three cohorts were created: RA with MBS, RA without MBS, and MBS without RA. Propensity score matching was performed using demographic and comorbidities. Primary outcomes included long-term safety, nutritional complications, and RA disease-modifying indicators such as medication use and inflammatory markers. One thousand nine-hundred thirty-one patients with RA who underwent MBS were matched 1:1 with controls. Patients with RA experienced higher nutritional complications including vitamin D (52.4% versus 42.7%), B12 (18.0% versus 14.0%), and iron deficiency (11.5% versus 8.5%). Sleeve gastrectomy was associated with fewer complications than Roux-en-Y gastric bypass. Postoperatively, patients with RA showed significant reductions in use of corticosteroids (34.3% versus 53.6%), tumor necrosis factor inhibitors (6.3% versus 14.5%), and disease-modifying antirheumatic drugs (9.7% versus 31.6%), along with lower inflammatory makers levels. Five-year mortality was lower in the RA surgical group (1.8% versus 3.8%). MBS in patients with RA is associated with improved disease control and reduced mortality, though higher nutritional risks warrant careful postoperative monitoring and multidisciplinary care.

20 March 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
VMValentin Mocanu
Valentin Mocanu
MWMélissa V. Wills
Mélissa V. Wills
SNSalvador Navarrete
Salvador Navarrete
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
XZXinlei Zhu
Xinlei Zhu
Jerry DangJerry Dang
Jerry Dang

19 February 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
KHKarl Hage
Karl Hage
MWMélissa V. Wills
Mélissa V. Wills
VMValentin Mocanu
Valentin Mocanu
JBJuan S. Barajas-Gamboa
Juan S. Barajas-Gamboa
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
Jerry DangJerry Dang
Jerry Dang
Abdominal Wall Hernias (AWHs) are common in patients with obesity, yet the optimal management approach and outcomes of concurrent bariatric surgery and hernia repair remain unclear. To compare outcomes of patients who underwent concurrent AWH repair and bariatric surgery with those who had bariatric surgery alone. National deidentified database. We conducted a retrospective analysis of the 2023 Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program database, which recently incorporated new Current Procedural Terminology codes capturing detailed hernia characteristics. Of 180,544 patients undergoing bariatric surgery, 1.3% (2292) of patients underwent concurrent AWH. These patients were older (47.6 ± 11.4 vs. 42.9 ± 11.9 years; P < .001), had higher body mass index (46.1 ± 11.4 vs. 45.1 ± 7.7 kg/m2; P < .001), and more comorbidities. Most repaired hernias were primary (90.1%), reducible (71.4%), and small-to-medium sized (<3 cm) (94.9%). Concurrent procedures had longer operative times (122.2 ± 64.5 vs. 84.1 ± 48.4 min) and hospital stays (1.5 ± 1.8 vs. 1.2 ± 1.1 days). Reoperation (2.1% vs. .8%), readmission (4.8% vs. 2.9%), serious complications (4.1% vs. 2.5%), and mortality (.3% vs. .07%) were significantly higher with concurrent repair (all P < .001). Multivariable logistic regression analysis identified medium hernia size (3-10 cm) (odds ratio [OR] 1.87), increased age (OR 1.10), history of venous thromboembolism (OR 1.49), and Roux-en-Y gastric bypass (RYGB) (OR 1.72) as independent predictors of serious complications. This large-scale national analysis demonstrates that concurrent AWH repair during bariatric surgery is uncommon and might be associated with higher short-term morbidity. These findings should be interpreted as descriptive and hypothesis-generating, highlighting patient- and hernia-specific factors that may inform perioperative risk stratification and shared decision-making, particularly in patients with medium-sized hernias (3-10 cm) or those undergoing RYGB.

18 August 2025 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
MWMélissa V. Wills
Mélissa V. Wills
JLJack Loesch
Jack Loesch
JBJuan S Barajas-Gamboa
Juan S Barajas-Gamboa
GRGabriela Restrepo Rodas
Gabriela Restrepo Rodas
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
VMValentin Mocanu
Valentin Mocanu